brainy: I wonder if the shorts can afford paying FIVE more years of margin interests and dividends. The shorts may very well extinct in 5 more months, maximum. Just so that you know and do not hold your breath for it.
Sentiment: Strong Buy
Brainy, you are very misinformed. APD334 is an S1P1 receptor agonist which means it's MOA is identical to Gilenya, not ACTH. If it ever gets approved, it will compete with all the other Disease Modifiers, not ACTH. You are comparing apples to oranges, sorry!!
ARNA stats from Yahoo:
Profit margin: NA
Operating Margin: -207%
Return on equity: -156%,
Revenue/share (ttm): 0.14
Yeah, I'ma sell all my QCOR for this obvious winner.
Are there really people dumb enuf to fall for this #$%$?